Drug Approval | January 10, 2023
Fesoterodine Fumarate Extended-Release Tablets, 4 mg and 8 mg, (RLD Toviaz®) had estimated annual sales of USD 177 million in the U.S. (IQVIA MAT September 2022).
Zydus is the first company to receive final approval and launch Topiramate Extended-Release Capsules, USP 25 mg, 50 mg, and 100 mg in the United States.
Fesoterodine Fumarate Extended-Release Tablets, 4 mg and 8 mg, have an estimated market size of US$ 177 million for twelve months ending Sep 2022
The estimated national burden of asthma in India is at 17.23 million with an overall prevalence of 2.05% and out of this, approximately 30 lakh patients can be classified under “inadequately controlled”
Supriya Lifescience Limited has informed that the European Directorate for the Quality of Medicines (EDQM) has granted Attestation of Inspection (EU-GMP) for Lote API Facility, Ratnagiri, Maharashtra.
Triazolam tablets are used on a short-term basis to treat insomnia (difficulty falling asleep or staying asleep)
Fulvestrant Injection, 250 mg/5 mL, has an estimated market size of US $71 million for twelve months ending Sep 2022 according to IQVIA
Pregabalin Capsules have an estimated market size of US $244 million for twelve months ending Sep 2022 according to IQVIA
Subscribe To Our Newsletter & Stay Updated
